AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03478358
Drug: 177Lu-DOTA-EB-TATE 2
RxNorm normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Trial: NCT03478358
Drug: 177Lu-DOTA-EB-TATE 3
RxNorm normalized name: DOTA-TATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
Trial: NCT03478358
Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
Trial: NCT03478358
Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
Trial: NCT02967744
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs are among the most common pain treatments for patients with osteoarthritis.
Trial: NCT00940225
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00307294
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Trial: NCT00307294
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
Trial: NCT03182088
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive spinal anesthesia using Bupivacaine (10 mg).
Trial: NCT01114425
Drug: raltegravir (Isentress)
RxNorm normalized name: raltegravir Oral Tablet [Isentress]
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir (Isentress) 400 mg bid
Trial: NCT01402050
Drug: CERVIDIL (Dinoprostone)
RxNorm normalized name: dinoprostone Vaginal Insert [Cervidil]
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: INDUCTION OF LABOR
Trial: NCT02028221
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
Trial: NCT02562053
Drug: Combined oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
Trial: NCT01155232
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Forteo (teriparatide)pen daily for 24 months
Trial: NCT01661296
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
Trial: NCT00493324
Drug: alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular
Trial: NCT00493324
Drug: polyvalent pneumococcal vaccine
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01080534
Drug: Tacrolimus 5 mg Capsule
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Trial: NCT02505997
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
Trial: NCT02505997
Drug: Delafloxacin
RxNorm normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
Trial: NCT02407821
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
Trial: NCT00352560
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 300 mg, once daily, 30 days.
Trial: NCT02324569
Drug: SYR-472
RxNorm normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-472 tablets
Trial: NCT00990236
Drug: Enoxaparin dose adjusted Lovenox based on TEG
RxNorm normalized name: enoxaparin Injectable Solution [Lovenox]
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
Trial: NCT00990236
Drug: Enoxaparin 30 mg BID
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin dose of 30 mg twice a day without any adjustments
Trial: NCT01489488
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
Trial: NCT01489488
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
Trial: NCT01489488
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
Trial: NCT01489488
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
Trial: NCT01489488
Drug: Riociguat (BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
Trial: NCT00452348
Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
Trial: NCT01523860
Drug: Rituximab, Mitoxantrone, Bendamustine
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
Trial: NCT03684395
Drug: DOACs: Rivaroxaban, Dabigatran, Apixaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Trial: NCT00205738
Drug: Risperidone, Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04988646
Drug: Acyclovir 200 MG
RxNorm normalized name: acyclovir 200 MG
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT04988646
Drug: Acyclovir 400 MG
RxNorm normalized name: acyclovir 400 MG
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT04988646
Drug: Zovirax 200 MG Tablet
RxNorm normalized name: acyclovir 200 MG [Zovirax]
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT00452348
Drug: Fluticasone propionate 250 mcg BID
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 mcg BID
Trial: NCT04988646
Drug: Zovirax 400 MG Tablet
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered with 240 mL of water
Trial: NCT02049281
Drug: Vintafolide
RxNorm normalized name: vintafolide
DrugBank: Vintafolide (DB05168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
Trial: NCT00005045
Drug: carboxyamidotriazole
RxNorm normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01275664
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and PO
Trial: NCT01275664
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IP
Trial: NCT01275664
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IP
Trial: NCT01275664
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01275664
Drug: Granisetron Transdermal Patch
RxNorm normalized name: granisetron Transdermal System
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply one patch to upper arm
Trial: NCT04254471
Drug: carboplatin + etoposide
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and etoposide are background treatment.
Trial: NCT01559727
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
Trial: NCT01559727
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
Trial: NCT00101959
Drug: Rebif
RxNorm normalized name: Rebif
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01559727
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Trial: NCT00889486
Drug: TZP-102
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03789006
Drug: Antithymocyte Immunoglobulin (Rabbit)
RxNorm normalized name: antithymocyte immunoglobulin (rabbit)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction agent for living donor kidney transplantation
Trial: NCT03789006
Drug: Interleukin 2 Receptor Antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction agent for living donor kidney transplantation
Trial: NCT00615667
Drug: tacrolimus (FK506)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Trial: NCT00599924
Drug: sunitinib + FOLFOX
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
Trial: NCT04638491
Drug: Lurbinectedin for injection
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the first day of each cycle, patients with advancedsolid tumors or small cell lung cancer were treated with Lurbinectedin for injection
Trial: NCT00002876
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002876
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02381288
Drug: TAK-448
RxNorm normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 solution for subcutaneous injection
Trial: NCT02381288
Drug: TAK-448 Placebo
RxNorm normalized name: TAK-448
DrugBank: TAK-448 (DB11975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 placebo-matching solution for subcutaneous injection
Trial: NCT03940404
Drug: Anlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Trial: NCT01738360
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180
Trial: NCT01397084
Drug: esomeprazole 20 mg
RxNorm normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg once daily for 8 weeks
Trial: NCT00719134
Drug: Maxalt
RxNorm normalized name: Maxalt
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anti-migraine drug
Trial: NCT00369187
Drug: large protein molecule
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00764556
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
Trial: NCT02534636
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02534636
Drug: Interferon alpha-2a recombinant
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534636
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00141947
Drug: bexarotene (Targretin)
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01592981
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
Trial: NCT01592981
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
Trial: NCT03686787
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A split face study of oral tranexamic acid in combination with laser treatment
Trial: NCT02743260
Drug: pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743260
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02743260
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02743260
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02743260
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03126760
Drug: Acthar Gel
RxNorm normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acthar Gel 1 mL (80U) for subcutaneous injection
Trial: NCT03517956
Drug: Rogaratinib (BAY1163877)
RxNorm normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part.
Trial: NCT03517956
Drug: Copanlisib (BAY80-6946)
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part.
Trial: NCT00592384
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
Trial: NCT00333814
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 350 µg; injection drug delivery system at Day 0
Trial: NCT00333814
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 700 µg injection drug delivery system at Day 0
Trial: NCT00333814
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection at Day 0
Trial: NCT00109798
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient will take drug on day 1-5 of 28 day schedule
Trial: NCT00109798
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will have IV on days 2-6 on a 28-day schedule
Trial: NCT03555591
Drug: Trelagliptin
RxNorm normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Trelagliptin tablets
Trial: NCT00684593
Drug: Navarixin 10 mg
RxNorm normalized name: Navarixin
DrugBank: Navarixin (DB11711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navarixin capsules orally, once daily for 28 days.
Trial: NCT00670683
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Trial: NCT02433483
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by either intrathecal (IT) or intravenous (IV) route.